全文获取类型
收费全文 | 1341篇 |
免费 | 160篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 105篇 |
妇产科学 | 19篇 |
基础医学 | 158篇 |
口腔科学 | 41篇 |
临床医学 | 159篇 |
内科学 | 282篇 |
皮肤病学 | 18篇 |
神经病学 | 165篇 |
特种医学 | 173篇 |
外科学 | 158篇 |
综合类 | 35篇 |
预防医学 | 63篇 |
眼科学 | 7篇 |
药学 | 47篇 |
中国医学 | 5篇 |
肿瘤学 | 57篇 |
出版年
2023年 | 2篇 |
2022年 | 6篇 |
2021年 | 26篇 |
2020年 | 13篇 |
2019年 | 17篇 |
2018年 | 47篇 |
2017年 | 44篇 |
2016年 | 50篇 |
2015年 | 46篇 |
2014年 | 46篇 |
2013年 | 73篇 |
2012年 | 53篇 |
2011年 | 56篇 |
2010年 | 68篇 |
2009年 | 73篇 |
2008年 | 55篇 |
2007年 | 54篇 |
2006年 | 43篇 |
2005年 | 35篇 |
2004年 | 33篇 |
2003年 | 27篇 |
2002年 | 29篇 |
2001年 | 30篇 |
2000年 | 24篇 |
1999年 | 18篇 |
1998年 | 64篇 |
1997年 | 57篇 |
1996年 | 57篇 |
1995年 | 50篇 |
1994年 | 29篇 |
1993年 | 41篇 |
1992年 | 20篇 |
1991年 | 24篇 |
1990年 | 23篇 |
1989年 | 17篇 |
1988年 | 25篇 |
1987年 | 23篇 |
1986年 | 17篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 17篇 |
1982年 | 3篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1978年 | 2篇 |
1977年 | 10篇 |
1976年 | 9篇 |
1975年 | 3篇 |
1971年 | 1篇 |
1938年 | 1篇 |
排序方式: 共有1511条查询结果,搜索用时 15 毫秒
51.
52.
Oscar Bernal‐Pacheco MD Genko Oyama MD PhD Kelly D. Foote MD Yunfeng E. Dai MS Samuel S. Wu PhD Charles E. Jacobson IV BS Natlada Limotai MD Pamela R. Zeilman ARNP Janet Romrell PA Nelson Hwynn DO Ramon L. Rodriguez MD Irene A. Malaty MD Michael S. Okun MD 《Neuromodulation》2013,16(1):35-40
Objectives: To screen for potentially underreported behavioral changes in patients with idiopathic Parkinson's disease (PD) pre‐ and post‐deep brain stimulation (DBS), a retrospective data base review was performed. Methods: In total, 113 patients who underwent unilateral or bilateral DBS at the University of Florida in either subthalamic nucleus or globus pallidus internus for PD were screened for behavioral issues by asking about the presence or absence of seven neuropsychiatric symptoms (panic, fear, paranoia, anger, suicidal flashes, crying, and laughing). Results: There was a high prevalence of fear (16.3%), panic (14.0%), and anger (11.6%) at baseline in this cohort. In the first six months following DBS implantation, anger (32.6%), fear (26.7%), and uncontrollable crying (26.7%) were the most frequent symptoms reported. Those symptoms also were present following six months of DBS surgery (30.2%, 29.1%, and 19.8%, respectively). New uncontrollable crying occurred more in the acute postoperative stage (less than or equal to six months) (p= 0.033), while new anger occurred more in the chronic postoperative stage (greater than six months) (p= 0.017). The frequency of uncontrollable laughing significantly increased with bilateral DBS (p= 0.033). Conclusions: Many of the neuropsychiatric issues were identified at preoperative baseline and their overall occurrence was more than expected. There was a potential for worsening of these issues post‐DBS. There were subtle differences in time course, and in unilateral vs. bilateral implantations. Clinicians should be aware of these potential behavioral issues that may emerge following DBS therapy, and should consider including screening questions in preoperative and postoperative interviews. Standardized scales may miss the presence or absence of these clinically relevant issues. 相似文献
53.
Cognitive function and patient‐reported memory problems after radiotherapy for cancers at the skull base: A cross‐sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory‐Head and Neck Module 下载免费PDF全文
Chase C. Hansen MD Joshua B. Smith BS Abdallah S. R. Mohamed MD MSc Collin F. Mulcahy MD Jeffrey S. Wefel PhD Katherine A. Hutcheson PhD Kelsey Chrane PA Jack Phan MD PhD Steven J. Frank MD Adam S. Garden MD Blaine D. Smith BS Hillary Eichelberger BA Carthal Anderson BS Colton McCoy BS Marina Horiates BS Conner Patrick BS Sarah Floris BS Chloe French BS Beth M. Beadle MD PhD William H. Morrison MD Shirley Y. Su MD Carol M. Lewis MD Michael E. Kupferman MD Jason M. Johnson MD Heath D. Skinner MD PhD Stephen Y. Lai MD PhD Ehab Y. Hanna MD David I. Rosenthal MD Clifton D. Fuller MD PhD G. Brandon Gunn MD The MD Anderson Head Neck Cancer Symptom Working Group 《Head & neck》2017,39(10):2048-2056
54.
55.
Saiz María Gutierrez-Carvajal Amanda Galvez Xiomara Lorente José Antonio Alvarez Juan Carlos 《International journal of legal medicine》2019,133(5):1397-1400
International Journal of Legal Medicine - Genetic data from 21 autosomal insertion-null (INNULs) markers found in the InnoTyper® 21 Human DNA Analysis (InnoGenomics®) was evaluated in 190... 相似文献
56.
57.
Choice of Vein‐Harvest Technique for Coronary Artery Bypass Grafting: Rationale and Design of the REGROUP Trial 下载免费PDF全文
Marco A. Zenati MD MSc J. Michael Gaziano MD MPH Joseph F. Collins ScD Kousick Biswas PhD Jennifer M. Gabany MSN CRNP CCRC Jacquelyn A. Quin MD MPH Jerene M. Bitondo PA‐C Faisal G. Bakaeen MD Rosemary F. Kelly MD A. Laurie Shroyer PhD Deepak L. Bhatt MD MPH 《Clinical cardiology》2014,37(6):325-330
The Randomized Endo‐vein Graft Prospective (REGROUP) trial ( ClinicalTrials.gov NCT01850082) is a randomized, intent‐to‐treat, 2‐arm, parallel‐design, multicenter study funded by the Cooperative Studies Program (CSP No. 588) of the US Department of Veterans Affairs. Cardiac surgeons at 16 Veterans Affairs (VA) medical centers with technical expertise in performing both endoscopic vein harvesting (EVH) and open vein harvesting (OVH) were recruited as the REGROUP surgeon participants. Subjects requiring elective or urgent coronary artery bypass grafting using cardiopulmonary bypass with use of ≥1 saphenous vein graft will be screened for enrollment using pre‐established inclusion/exclusion criteria. Enrolled subjects (planned N = 1150) will be randomized to 1 of the 2 arms (EVH or OVH) after an experienced vein harvester has been assigned. The primary outcomes measure is the rate of major adverse cardiac events (MACE), including death, myocardial infarction, or revascularization. Subject assessments will be performed at multiple times, including at baseline, intraoperatively, postoperatively, and at discharge (or 30 days after surgery, if still hospitalized). Assessment of leg‐wound complications will be completed at 6 weeks after surgery. Telephone follow‐ups will occur at 3‐month intervals after surgery until the participating sites are decommissioned after the trial's completion (approximately 4.5 years after the full study startup). To assess long‐term outcomes, centralized follow‐up of MACE for 2 additional years will be centrally performed using VA and non‐VA clinical and administrative databases. The primary MACE outcome will be compared between the 2 arms, EVH and OVH, at the end of the trial duration. 相似文献
58.
Diffusion in gel-enzyme-linked immunosorbent assay—a new serological test for leptospirosis 下载免费PDF全文
A new serological test, diffusion in gel-enzyme-linked immunosorbent assay (DIG-ELISA) was developed and compared with the microscopic agglutination test (MAT) for the serological diagnosis of leptospirosis. The results suggest that DIG-ELISA is a viable alternative to the MAT because of its simplicity, sensitivity, versatility and potential for standardisation. 相似文献
59.
Iñigo Gabilondo MD Elena H. Martínez‐Lapiscina MD Eloy Martínez‐Heras MSc Elena Fraga‐Pumar BO Sara Llufriu MD Santiago Ortiz MD Santiago Bullich PhD Maria Sepulveda MD Carles Falcon PhD Joan Berenguer MD Albert Saiz MD Bernardo Sanchez‐Dalmau MD Pablo Villoslada MD 《Annals of neurology》2014,75(1):98-107
60.
Suvi Liimatainen Maria Peltola Lidia Sabater Mahdi Fallah Elham Kharazmi Anna‐Maija Haapala Prasun Dastidar Mikael Knip Albert Saiz Jukka Peltola 《Epilepsia》2010,51(5):760-767
Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined. Methods: We analyzed GADA with a radioimmunoassay in sera of 253 well‐characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies. Results: GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [≥1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA‐positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra‐TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39–4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001). Discussion: High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. 相似文献